AnuBio utilizes two mutually supporting platforms—TRAILBLAZER and PHENOMS—to revolutionize the understanding of the immune system and de-risk every step of drug discovery.

Overview

TRAILBLAZER

Foundational model of immune system

I. Molecular model of animal and human immune system perturbations with single-cell resolution

II. Drug developability modeling

III. Clinical trial modeling

  • Predicts the probability of drug discovery success by integrating information about desirable and undesirable cellular responses in animal models and humans with candidate drugs' developability characteristics and clinical trial modeling.

  • It translates the complex language of biology into business decisions, rationalizing target and drug selection at every step.

PHENOMS

Integrated drug and target discovery platform
Both technologies synergize, creating a closed-loop lab-AI research platform where PHENOMS provides real-world data and validation, while TRAILBLAZER rationalizes drug discovery by providing predictions about expected success at every step of the discovery process.
"A process cannot be understood by stopping it. Understanding must move with the flow of the process, must join it and flow with it.”
―Frank Herbert, Dune
Thanks to AnuBio's proprietary library, PHENOMS is the highest throughput combinatorial, phenotypic discovery platform for biologics, capable of exhaustively screening and deconvoluting all natural and synthetic cellular signaling. It is designed for discovery of drugs and targets, while simultaneously creating the largest proprietary dataset of biologically relevant perturbations of the immune system for training TRAILBLAZER, our foundational model of immune system.
Follow us on